Galera Therapeutics, Inc. Net Income Loss

• Galera Therapeutics, Inc. showed an increase of +886.2% in Net Income Loss from 2024 to 2025.
• This data is from Galera Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 19, 2026.
• XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 8 years of available data (2018 to 2025), Galera Therapeutics, Inc.'s Net Income Loss has grown by 729.5%.
• Historical annual values: Fiscal year 2025: $149.05 million | Fiscal year 2024: -$18.96 million | Fiscal year 2023: -$59.08 million | Fiscal year 2022: -$62.22 million | Fiscal year 2021: -$80.53 million | Fiscal year 2020: -$74.22 million | Fiscal year 2019: -$51.93 million | Fiscal year 2018: -$23.68 million.
• Data sourced from SEC EDGAR public filings as of June 23, 2026.

Last verified: June 23, 2026